Pharma industry reported 65 deals worth $6.4 billion as compared to the last 12-month average (January 2021 to December 2021) of 95 deals worth $19.4 billion in January 2022, the latest report from GlobalData said.
Samsung Biologics to acquire Biogen’s stake in Samsung Bioepis joint venture for $$2.3 billion; UCB SA, through its subsidiary, Zinc Merger Sub, Inc, to acquire Zogenix, Inc., a biopharmaceutical company for approximately $1.9 billion; and Merck KGaA, to acquire Exelead Inc for $780 million in cash, were the three major deals which contributed 77.6 per cent of the total deal value during January 2022, the report notified.
It also said that the industry reported 131 Venture Capital (VC) deals worth $4.4 billion in January 2022, compared to the last 12-month average (January 2021 to December 2021) of 175 deals worth $5.3 billion.
Eikon Therapeutics Inc raising $517.8 million in series B round of financing to advance its mission of inventing new therapies that address grievous illnesses; Alumis Inc raising $200 million in series B financing to advance precision medicines for autoimmune diseases; and Metagenomi Inc, raising $175 million in series B financing to further develop its set of next-generation gene-editing tools were the major VC deals reported in January 2022, the report concluded.